NOVO-B.CO CHMP opinion: Thursday, July 23, 2026
Variation type II · Wegovy · Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to reflect clinical results related to adults with overweight/obesity and metabolic dysfunction-associated steatohepatitis (MASH) based on interim results from phase 3a clinical study NN9931-4553 (E
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.